Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Jaime Guzman¹, Oralia Gomez-Ramirez², Susanne M. Benseler³, Roberta A. Berard⁴, Rollin Brant⁵, Ciaran M. Duffy⁶, Roman Jurencak⁷, Kiem Oen⁸, Ross E. Petty⁹, Natalie J. Shiff¹⁰ and Lori B. Tucker¹¹, ¹Pediatric Rheum/Rm K4-122, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Anthropology, University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Statistics, University of British Columbia, Vancouver, BC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, BC Children's Hosptial, Vancouver, BC, Canada, ¹⁰Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 298 • 2013 ACR/ARHP Annual Meeting
Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare?
Vanessa B Miotto e Silva¹, Sônia A.V. Mitraud², Rita NV Furtado³, Jamil Natour³ and Maria Teresa Terreri¹, ¹Pediatrics, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil, ²Radiology and Diagnostic Imaging, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil, ³Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and has variable prognosis, characterized by periods of activity and remission.…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 2677 • 2013 ACR/ARHP Annual Meeting
Disease Progression Into Adulthood In Patients With Juvenile Idiopathic Arthritis – a Longitudinal 30 Year Follow-Up Study
Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: The aim of the study was to assess disease activity and health status in a previously studied cohort of patients with juvenile idiopathic arthritis…
Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Shumpei Yokota^1,2, Yasuhiko Itoh^2,3, Tomohiro Morio^2,4, Naokata Sumitomo^2,5 and Seiji Minota^2,6, ¹Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ²The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan, ³pediatrics, Nippon Medical School, Tokyo, Japan, ⁴Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵pediatrics, Nihon University School of Medicine, tokyo, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…
Abstract Number: 2212 • 2013 ACR/ARHP Annual Meeting
Development Of Tools To Facilitate Shared Decision Making About Medications For Juvenile Idiopathic Arthritis – A Project Of The Pediatric Rheumatology Care and Outcomes Improvement Network
Esi Morgan DeWitt¹, Ellen A. Lipstein², Katie Staun³, Linda Scherer⁴, Janalee Taylor⁵, Carole M. Lannon⁴ and William B. Brinkman⁶, ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵William S. Rowe Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Medication options for juvenile idiopathic arthritis (JIA) are increasing. Medications differ on a variety of attributes, including mechanisms of action, dosing intervals, modes of…
Abstract Number: 2191 • 2013 ACR/ARHP Annual Meeting
Intestinal Microbiome In Polyarticular Juvenile Idiopathic Arthritis: A PILOT Study
Petra C.E. Hissink Muller^1,2, A.E. Budding³, Cornelia F. Allaart⁴, Danielle M.C. Brinkman^1,5, Taco W. Kuijpers⁶, Michiel Westedt¹, J. Merlijn van den Berg⁷, Lisette W.A. Van Suijlekom-Smit⁸, Marion A.J. Van Rossum⁹, Tim G.J. de Meij¹⁰ and Rebecca Ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade Institute, Amsterdam, Netherlands, ³Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁶Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ⁷Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁹Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ¹⁰Pediatric Gastroenterology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: The intestinal microbiome may play a role in the pathogenesis of Juvenile Idiopathic Arthritis (JIA). In IBD patients an overall decrease in microbial diversity of…
Abstract Number: 2192 • 2013 ACR/ARHP Annual Meeting
Vitamin D Receptor Polymorphisms In A Cohort Of Italian Patients With Juvenile Idiopathic Arthritis
Fernanda Falcini¹, Francesca Marini², Donato Rigante³, Federico Bertini⁴, Gemma Lepri⁵, Stefano Stagi⁶, Marco Matucci Cerinic⁷ and Maria Luisa Brandi⁸, ¹Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ²Surgery and Translational Medicine, University of Florence, Firenze, Italy, ³Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy, ⁴Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, ⁵Department of Internal Medicine, Section of Rheumatology, Transition Clinic, University of Florence, Florence, Italy, ⁶Pediatric Endocrinology Unit, Anna Meyer Children’s Hospital, University of Florence, Firenze, Italy, ⁷Department of Biomedicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁸Surgery and Translational Medicine, University of Florence, Florence, Italy
Background/Purpose: A role for vitamin D has been hypothesized in generating disease activity for patients with juvenile idiopathic arthritis (JIA): specific polymorphisms of vitamin D…
Abstract Number: 2207 • 2013 ACR/ARHP Annual Meeting
Plasma Cytokine Concentrations Are Associated With Folate Perturbations and Methotrexate Polyglutamate Accumulation In The Peripheral Blood Of Juvenile Idiopathic Arthritis Patients Treated With Low-Dose Methotrexate
Ryan S. Funk¹, Leon van Haandel¹, Marcia Chan², Lanny J. Rosenwasser², Andrew Lasky³, Maria F. Ibarra⁴, Mark F. Hoeltzel⁵, J.S. Leeder¹ and Mara L Becker⁶, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Pediatric Immunology Research, Children's Mercy Hospital, Kansas City, MO, ³Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, ⁶Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Methotrexate inhibits the production of inflammatory cytokines, but is also an antifolate. The activity of MTX is thought to depend on the formation of…
Abstract Number: 2001 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Sarah Ringold¹, Shannon Grant², Charmaine Girdish³, Carol A. Wallace⁴ and Sean Sullivan⁵, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Axio Research LLC, Seattle, WA, ³Research, CVS Caremark, Scottsdale, AZ, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…
Abstract Number: 1021 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis
Mira van Veenendaal¹, Robert Hemke², Marjolein I. Bos³, Mario Maas⁴, Marion A. J. Van Rossum³ and Taco W. Kuijpers⁵, ¹Departments of Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ²Departments of Radiology, Academic Medical Center (AMC), Amsterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Radiology, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands
Background/Purpose: Despite clinical remission, a substantial proportion of Juvenile Idiopathic Arthritis (JIA) patients will flare after a period of inactive disease. MRI has proven to…
Abstract Number: 2005 • 2012 ACR/ARHP Annual Meeting
Clinical Course and Outcomes of Children with Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Uveitis
Sheila T. Angeles-Han¹, Steven Yeh², Courtney McCracken³, Larry B. Vogler⁴, Kelly A. Rouster-Stevens⁵, Christine W. Kennedy⁶, Matthew Kent⁴, Kirsten Jenkins⁷, Scott Lambert⁸, Carolyn Drews-Botsch⁹ and Sampath Prahalad¹⁰, ¹Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ⁵Pediatric Rheumatologist, Emory Children's Center, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, ⁹Epidemiology, Emory University School of Public Health, Atlanta, GA, ¹⁰Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Uveitis can lead to vision loss and blindness. Few studies focus on the outcomes of children with both juvenile idiopathic arthritis-associated uveitis (JIA-U) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.